Literature DB >> 2998787

Chemotherapy of herpesvirus infections: present successes and future hopes.

S Crowe, J Mills.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2998787     DOI： 10.1007/bf02014424

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN： 0722-2211            Impact factor:   3.267


× No keyword cloud information.
  50 in total

1.  Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation.

Authors:  D W Hanto; G Frizzera; K J Gajl-Peczalska; K Sakamoto; D T Purtilo; H H Balfour; R L Simmons; J S Najarian
Journal:  N Engl J Med       Date:  1982-04-15       Impact factor: 91.245

2.  Suppression of frequently recurring genital herpes. A placebo-controlled double-blind trial of oral acyclovir.

Authors:  S E Straus; H E Takiff; M Seidlin; S Bachrach; L Lininger; J J DiGiovanna; K A Western; H A Smith; S N Lehrman; T Creagh-Kirk
Journal:  N Engl J Med       Date:  1984-06-14       Impact factor: 91.245

Review 3.  The spectrum of antiviral activities of acyclovir in vitro and in vivo.

Authors:  P Collins
Journal:  J Antimicrob Chemother       Date:  1983-09       Impact factor: 5.790

4.  Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes.

Authors:  A E Nilsen; T Aasen; A M Halsos; B R Kinge; E A Tjøtta; K Wikström; A P Fiddian
Journal:  Lancet       Date:  1982-09-11       Impact factor: 79.321

5.  Adenine arabinoside therapy of biopsy-proved herpes simplex encephalitis. National Institute of Allergy and Infectious Diseases collaborative antiviral study.

Authors:  R J Whitley; S J Soong; R Dolin; G J Galasso; L T Ch'ien; C A Alford
Journal:  N Engl J Med       Date:  1977-08-11       Impact factor: 91.245

6.  Acyclovir versus vidarabine in herpes simplex encephalitis. Randomised multicentre study in consecutive Swedish patients.

Authors:  B Sköldenberg; M Forsgren; K Alestig; T Bergström; L Burman; E Dahlqvist; A Forkman; A Frydén; K Lövgren; K Norlin
Journal:  Lancet       Date:  1984-09-29       Impact factor: 79.321

7.  Treatment of cytomegalovirus retinitis with 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine.

Authors:  D Felsenstein; D J D'Amico; M S Hirsch; D A Neumeyer; D M Cederberg; P de Miranda; R T Schooley
Journal:  Ann Intern Med       Date:  1985-09       Impact factor: 25.391

8.  Activity of 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine in the treatment of cytomegalovirus pneumonia.

Authors:  D H Shepp; P S Dandliker; P de Miranda; T C Burnette; D M Cederberg; L E Kirk; J D Meyers
Journal:  Ann Intern Med       Date:  1985-09       Impact factor: 25.391

9.  Unique spectrum of activity of 9-[(1,3-dihydroxy-2-propoxy)methyl]-guanine against herpesviruses in vitro and its mode of action against herpes simplex virus type 1.

Authors:  Y C Cheng; E S Huang; J C Lin; E C Mar; J S Pagano; G E Dutschman; S P Grill
Journal:  Proc Natl Acad Sci U S A       Date:  1983-05       Impact factor: 11.205

10.  9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine: a selective inhibitor of herpes group virus replication.

Authors:  A K Field; M E Davies; C DeWitt; H C Perry; R Liou; J Germershausen; J D Karkas; W T Ashton; D B Johnston; R L Tolman
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205
View more
  1 in total

Review 1.  The future of antiviral chemotherapy.

Authors:  S Crowe; J Mills
Journal:  Dermatol Clin       Date:  1988-10       Impact factor: 3.478
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.